HanchorBio Presents Preclinical Data on HCB301 at SITC 2025
November 06, 2025 | 11:54
HanchorBio Inc., today announced that the preclinical data on HCB301, has been accepted for presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer, taking place November 5-9, 2025, in National Harbor, Maryland.
HanchorBio Secures US Patent for Innovative SIRPα/CD47 Fusion Protein HCB101
October 22, 2025 | 17:17
HanchorBio today announced that its proprietary HCB101, a SIRPα/CD47 fusion protein candidate, has been officially granted a US patent (Patent No. 12,447,195) by the United States Patent and Trademark Office (USPTO).
Mobile Version